Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Mitchell Shuster Steiner Insider Profile
4 Followers
Mitchell Shuster Steiner, CEO, Director at Oncternal Therapeutics, holds 7.09M shares in Veru (Ticker: VERU), holds 6.54M shares in Oncternal Therapeutics (Ticker: ONCT). Most recently, Mitchell Shuster Steiner Sold ― shares of Veru on May 24, 2024 for an estimated value of 87.34K.
Mitchell Shuster Steiner Oncternal Therapeutics (ONCT)CEO, Director
Oncternal Therapeutics (ONCT)
CEO, Director
Ranked #10,920 out of 98,042 Corporate Insiders
Profitable Transactions
8 out of 15 Profitable Transactions
Average Return
+11.50%
Average return per transaction
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Mitchell Shuster Steiner holds in companies
Most Profitable Insider Trade
The most profitable trade made by Mitchell Shuster Steiner
Mitchell Shuster Steiner's Trading History
Oncternal Therapeutics
Jul 16, 2012
CEO, Director
Informative Sell
464.70K
$45.79M
Veru
May 24, 2024
President & CEO, Director
Informative Sell
87.34K
$6.40M
List of latest transactions for each holding click on a transaction to see Mitchell Shuster Steiner's performance on stock
You May Also Like
Mitchell Shuster Steiner insider profile FAQ
What is the percentage of profitable transactions made by Mitchell Shuster Steiner?
The percentage of profitable transactions made by Mitchell Shuster Steiner is 53%.
What is the average return per transaction made by Mitchell Shuster Steiner?
The average return per transaction made by Mitchell Shuster Steiner is 11.50%.
What stocks does Mitchell Shuster Steiner hold?
Mitchell Shuster Steiner holds: ONCT, VERU stocks.
What was Mitchell Shuster Steiner’s latest transaction?
Mitchell Shuster Steiner latest transaction was an Informative Sell of $87.34K.
What was Mitchell Shuster Steiner's most profitable transaction?
Mitchell Shuster Steiner’s most profitable transaction was an Informative Buy of VERU stock on June 12, 2017. The return on the trade was 81.40%.
What is Mitchell Shuster Steiner's role in Oncternal Therapeutics?
Mitchell Shuster Steiner's role in Oncternal Therapeutics is CEO, Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.